RZLT241220C5000
- 0.35
- 0.000.00%
Rezolute Newsroom
Rezolute, Inc. Advances Late-Stage Trials for Rare Disease Therapies
Rezolute Granted FDA Orphan Designation for Treatment of Hypoglycemia
Is Rezolute, Inc. (RZLT) the Best Multibagger Stock to Buy Heading Into 2025?
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Announces Target Price $12
H.C. Wainwright Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $14
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $12
JMP Securities Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $8
Rezolute's Promising Pipeline and Financial Stability Drive Buy Rating and Increased Price Target
Rezolute | 10-Q: Q1 2025 Earnings Report
Express News | Rezolute Q1 EPS $(0.22) Beats $(0.33) Estimate
Rezolute | 8-K: Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Express News | Rezolute Inc: Phase 3 Sunrize Study on Track; U.S. Enrollment Expected to Commence in First Part of 2025
Express News | Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Express News | Rezolute Q1 Income From Operations USD -16.941 Million
Press Release: Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Wedbush Initiates Rezolute(RZLT.US) With Buy Rating, Announces Target Price $12
Rezolute to Participate in Upcoming Investor Conferences
Rezolute Price Target Announced at $12.00/Share by Wedbush
Rezolute Initiated With an Outperform at Wedbush